source
- Summit Therapeutics cancels $500 million public offering amid weak market conditionsSummit Therapeutics announced it is no longer pursuing a $500 million public offering, citing unfavorable market conditions. The biotech sector has recently seen record‑setting initial public offe…
- Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trialNovartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…